IMPACT #: Local Inventory #: form 04. Age at admission: d. mo yr. Postal code:

Similar documents
Invasive Bacterial Disease

Invasive Bacterial Disease

Meningococcal Disease and College Students

Alberta Health and Wellness Public Health Notifiable Disease Management Guidelines August Pneumococcal Disease, Invasive (IPD)

Of 142 cases where sex was known, 56 percent were male; of 127cases where race was known, 90 percent were white, 4 percent were

Microbiology Laboratory Directors, Infection Preventionists, Primary Care Providers, Emergency Department Directors, Infectious Disease Physicians

Streptococcus pneumoniae CDC

REQUIRED IMMUNIZATIONS

by author ESCMID Online Lecture Library Steroids in acute bacterial meningitis

Streptococcus Pneumoniae

Incidence per 100,

An Intriguing Case of Meningitis. Tiffany Mylius MLS (ASCP)

5/14/2015. Meagan Burns, MPH Massachusetts Adult Immunization Conference April relevant conflict. Grant Research/Support

Meningococcal Invasive Disease

Meningococcal Disease a resurgence of an old foe?

ANTIBIOTIC GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED MENINGITIS AND ENCEPHALITIS IN ADULTS

Influenza-Associated Pediatric Deaths Case Report Form

Aurora Health Care South Region EMS st Quarter CE Packet

Chapter 16 Pneumococcal Infection. Pneumococcal Infection. August 2015

Pneumococcal Vaccine in Children: current situation

GUIDELINE FOR THE MANAGEMENT OF MENINGITIS. All children with suspected or confirmed meningitis

Influenza-Associated Pediatric Mortality Case Report Form Form Approved OMB No

Menactra Intramuscular Injection

Severe β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy

Supplementary Appendix

Source: Portland State University Population Research Center (

Methicillin-Resistant Staphylococcus aureus (MRSA) S urveillance Report 2008 Background Methods

Reducing the burden of squamous cell carcinoma in Fanconi Anemia - Initial study questionnaire -

Vaccination Policy. Background: Meningococcal Disease on Campus

Name Age Birthday / / Sex Last First MI. Home Address Street Apt City State Zip Code Home phone: ( ) Cell phone: ( ) Name of parent(s) or guardian:

Haemophilus influenzae and its invisibility cloak. Anna Strain Virology Supervisor/VPD Reference Center Coordinator June 5, 2018

Haemophilus influenzae Surveillance Report 2012 Oregon Active Bacterial Core Surveillance (ABCs) Center for Public Health Practice Updated: July 2014

UK Meningitis Study CRF

Haemophilus influenzae, Invasive Disease rev Jan 2018

Past Medical History. Chief Complaint: Patient Name: Appointment Date: Page 1

Good Morning! Welcome Applicants! FRIDAY, N OVEMBER, 7 TH 2014

Pneumococcal 13-valent Conjugate Vaccine Biological Page

Pre-Admission Testing Questionnaire

HEALTH OFFICE, Poughkeepsie, NY Residential Student:

* Health Insurance Verification Form, submitted on line. Click on link. Mandatory Health Insurance Verification Form

The Premier Vein Center Evan Oblonsky MD 1051 W. Rand Road, Suite 104 Arlington Heights, IL Tel: Fax:

National Institute for Communicable Diseases -- Weekly Surveillance Report --

Required Certificate of Immunization

Immunodeficiencies HIV/AIDS

Dilemmas in the Management of Meningitis & Encephalitis HEADACHE AND FEVER. What is the best initial approach for fever, headache, meningisums?

Series of 2 doses, 6-12 months apart. One dose is 720 Elu/0.5ml (GSK) or 25 u/0.5 ml (Merck)

REGISTRY OF SEVERE CUTANEOUS ADVERSE REACTIONS TO DRUGS AND COLLECTION OF BIOLOGICAL SAMPLES. R e g i S C A R PATIENT'S DATA. Age country of birth

CNS Infections. Philip Gothard Consultant in Infectious Diseases Hospital for Tropical Diseases, London. Hammersmith Acute Medicine 2011

Central Nervous System Infection

DEADLINE To return completed form: Within 30 days of registering for classes

Immunization of Specific Populations (Immunosuppressed and Chronic Health Conditions)

InterQual Level of Care 2018 Index

Antibiotic Resistance Pattern of Blood and CSF Culture Isolates At NHLS Academic Laboratories (2005)

PAEDIATRIC Point Prevalence Survey. Ward Form

PATIENT HEALTH INFORMATION SHEET

Atgam (lymphocyte immune globulin, anti-thymocyte globulin [equine])

NORTHEAST HOSPITAL CORPORATION

Sickle Cell Disease. Edward Malters, MD

Vaccination and prophylaxis for asplenia: Guideline for clinicians

Postsplenectomy Syndrome Topic Review May 22, Done By: Sara AlArfaj, PharmD candidate KSU

12 Dynamic Interactions between Hematopoietic Stem and Progenitor Cells and the Bone Marrow: Current Biology of Stem Cell Homing and Mobilization

OREGON PUBLIC HEALTH, DHS IMMUNIZATION PROTOCOL FOR PHARMACISTS. PNEUMOCOCCAL POLYSACCHARIDE VACCINE 23-Valent Vaccine

Immunizing the Immunocompromised. Leilani T. Sanchez, MD, DPPS, DPIDSP Crowne Plaza Galleria Manila, 21 February 2013

Chickenpox Death. West Virginia Electronic Disease Surveillance System

11/9/2012. Group B Streptococcal Infections: Consensus and Controversies. Prevention of Early-Onset GBS Disease in the USA.

Secondary Immunodeficiency

Hths 2231 Laboratory 7 Infection

Radford University School of Nursing GRADUATE HEALTH RECORD FORM

If you have questions or concerns, please contact the Health Services office at (978)

Introduction to Emergency Medical Care 1

Chapter 26 - Hematologic_and_Renal_Emergencies

Lahey Clinic Internal Medicine Residency Program: Curriculum for Infectious Disease

Community Acquired Pneumonia

2. Does the patient have a diagnosis of chronic idiopathic thrombocytopenic purpura (ITP)?

CNS INFECTIONS 1 Acute meningitis

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Bone Marrow Transplantation

Investigation of a Neisseria meningitidis Serogroup A Case in the Meningitis Belt. January 2017

DEMOGRAPHIC INFORMATION

Pneumococcal Meningitis Meningitis is an inflammation of the lining around the brain and spinal cord. Most severe cases

Policy and Procedure Manual

Medicine - Dr. Hawar - Lecture 5 - CNS Infections I

Patient Last Name First Name Middle Name. Home Address City State Zip. Date of Birth Age Social Security # - - Cell Phone Home Phone Work Phone

In your own words, please write the reason you are here. Please be specific, putting in dates as necessary. Use the back of the form if needed.

Legal aspects in accidents and neglect.

Viral Infections. 1. Prophylaxis management of patient exposed to Chickenpox:

Mousa Suboh. Zaid Emad. Anas Abu -Humaidan

Description of the evidence collection method. (1). Each recommendation was discussed by the committee and a consensus

Development of C sporins. Beta-lactam antibiotics - Cephalosporins. Second generation C sporins. Targets - PBP s

HOSPITAL INFECTION CONTROL

Internal Medicine Certification Examination Blueprint

MENINGOCOCCAL MENINGITIS 101. An Overview for Parents, Teachers, Students and Communities

Care Guideline DRAFT for review cycle 08/02/17 CARE OF THE ADULT PNEUMONIA PATIENT

Pharmacy Prior Authorization

Osteomieliti STEOMIE

Pharmacy and Referrals Pharmacy Name, Street Address & Telephone #: Primary Care Physician s Name, Location & Telephone #:

ACGME Program Requirements for Graduate Medical Education in Pediatric Hematology-Oncology

Vancomycin: Class: Antibiotic.

SIB Chart Review Tool

Transcription:

- Date of birth: birth: Date of admission: year month day year month day Age at admission: d mo yr Postal code: Ethnic code: Hospital: Gender: 1 = male 2 = female 1 = Impact 2 = Other local, specify: Code A. GENERAL HEALTH OF INDIVIDUAL PRIOR TO THIS INFECTION: A.1. Health status prior to admission: (enter categories from list A.1 on back of sheet. Write N/A in unused box(es).) a) Most relevant health condition: Specific diagnosis: b) If additional relevant health condition present: Specific diagnosis: c) If additional relevant health condition present: Specific diagnosis: A.2. Immune status at time of admission: Choose best descriptors from list A.2 on reverse for individual s current immune status: (If only one category applies, write N/A in 2nd box) A.3. Prior Meningococcal infection known? If yes, a) Indicate age at onset: b) Infection syndrome: (use codes in C.2) Months Years If other: A.4. Risk Factors: a) Did the individual have known exposure to a recent case of meningococcal infection? b) Any biologic risk factors? If yes, choose all that apply: (write N/A in unused boxes) 1 = complement deficiency, newly demonstrated 2 = complement deficiency, previously known (A.2) 3 = absence or dysfunction of spleen, newly detected 4 = absence or dysfunction of spleen, previously known (A.2) 5 = low serum immunoglobulin levels, newly detected 6 = low serum immunoglobulin levels, previously known (A.2) 7 = corticosteroid treatment (except topical) 8 = other immunodeficiency, specify: V:/data/Forms/Mening Page 1 of 6 Jan 26/20

A.1. Health status prior to admission: 1 = Healthy for age (minor ailments only) 2 = Neoplasm of any kind, of current relevance - double check immune status 3 = Cardiovascular disorder 4 = Respiratory disorder (except otitis media, mild asthma) - double check immune status 5 = Hematologic disorder, non-malignant (eg. sickle cell disease) - double check immune status 6 = Neurological or developmental disorder 7 = Genitourinary or renal disorder - double check immune status 8 = Gastrointestinal or hepatic disorder 9 = Endocrine, nutritional or metabolic disorder 10 = Inherited immunodeficiency (eg. hypogammaglobulinemia) 11 = Bone, joint or connective tissue disorder - double check immune status 12 = Skin disorder (severe only) 13 = Effects of injury (CSF leakage, burns etc) 14 = Multi-system disorder or syndrome (eg Down syndrome) - double check immune status 15 = Chronic infection present (eg. HIV/AIDS, tuberculosis) - double check immune status 16 = Relevant concurrent acute infection (e.g. influenza) 17 = Other - specify on reverse A.2. Immune status at time of admission: 1 = Normal immunity for age, presumed or confirmed 2 = Immunosuppressed by cancer treatment (chemotherapy, radiation) 3 = Post-bone marrow transplantation 4 = Post-solid organ transplantation 5 = Inherited immune deficiency, as dictated by A.1) 10 above 6 = Immunosuppressed by corticosteroids and/or other current medications, for indications other than those listed in A.2) 2-4, above 7 = HIV/AIDS 8 = Spleen dysfunction or absence (including surgical removal) 9 = Low serum immunoglobulin levels, acquired (eg nephrotic syndrome) 10 = Complement deficiency or disorder 11 = Other acquired immunodeficiency (eg aplastic anemia) V:/data/Forms/Mening Jan 26/20

A. GENERAL HEALTH OF INDIVIDUAL PRIOR TO THIS INFECTION (continued): A.4. Risk Factors (continued): c) Any social or behavioural risk factors? If no/unknown skip to Section B. If yes, i) Cigarette smoking? ii) Alcoholism? 1 = none 2 = < 1pack/day 3 = > 1pack/day 4 = unknown iii) IV drug use? iv) Recent foreign travel? 1 = none 2 = Asia, country: 3 = Africa, country: 4 = Australia 5 = Europe: country: 6 = Other: specify: 7 = unknown v) Current college/university student? /NA vi) Group living arrangements? 1 = none 2 = residence/dormitory 3 = barracks 4 = homeless shelter 5 = other, specify: 6 = unknown B. IMMUNIZATION HISTORY: B.1. Did this infection occur despite prior meningococcal vaccination? Dose 1. 2. 3. 4., not vaccinated vaccination history Product/Manufacturer If no/unknown skip to C Date Given Verified with Imm. record YES NO V:/data/Forms/Mening Page 2 of 6 Jan 26/20

C. MANIFESTATIONS OF THE MENINGOCOCCAL INFECTION: C.1. Date of onset: C.2. Enter the categories that best describe the individual s illness. Enter all that apply. (Write N/A in unused boxes). Include location where specified: a c e b d f 1 = acute bacteremia without septic shock 8 = endophthalmitis 2 = acute bacteremia with septic shock 9 = seizure 3 = meningitis 10 = petechial rash 4 = chronic (subacute) meningococcemia 11 = bruising (ecchymosis) 5 = pneumonia 12 = skin necrosis, location: 6 = pericarditis 13 = other (describe): 7 = arthritis C.3. Was CSF examined: If no/unknown skip to C.4 If yes, a) Date sample collected: b) Indicate results below: Protein: Abnormal value: Glucose: Abnormal value: 1 = normal 2 = abnormal If abnormal, indicate exact value with units WBC: Abnormal value: 10 6 /L i) Neutrophils: ii) Lymphocytes: % % C.3. Blood sample counts within 24 hours of admission: 1 = normal 2 = abnormal If abnormal, indicate the maximum abnormal value and units (within 24 hours of admission) 3 = not done Hemoglobin: Abnormal value: WBC: Abnormal value: Platelets: Abnormal value: INR: Abnormal value: V:/data/Forms/Mening Page 3 of 6 Jan 26/20

D. ANTIBIOTIC HISTORY: D.1. Had the individual been on antibiotics immediately prior to admission/initial diagnosis? If no/unknown, skip to E If yes, a) Duration of continuous antibiotics: hours days (ND if no data) b) Route of antibiotic(s): 1=oral 2=intramuscular 3=intravenous 4=oral & injected 5=unknown c) Type of most recent antibiotic, specify: E. MICROBIOLOGY DATA: E.1. Is the isolate expected to be available for the study? (If yes, complete the Isolate Tracking Page) E.2. Positive cultures of Neisseria meningitidis were obtained from: (enter all that apply, write N/A in unused boxes) 1 = blood 5 = peritoneal fluid 2 = CSF 6 = pericardial fluid 3 = joint fluid 7 = other normally sterile site, specify: 4 = pleural fluid 8 = positive PCR test for meningococcus was obtained from blood or CSF E.3. Indicate the locally determined sero group of the Neisseria meningitidis: 1 = A 5 = Y 2 = B 6 = untypable 3 = C 7 = other, specify: 4 = W-135 8 = unknown/not done E.4. Indicate the antibiotic susceptibility of the Neisseria meningitidis with the following codes: 1 = susceptible n-susceptible (intermediate/high level resistance) 3 = not reported/na Penicillin Cefotaxime Ceftriaxone Penicillin MIC: Cefotaxime MIC: Ceftriaxone MIC:... mg/l or mcg/ml (Non-susceptible > 0.12mg/L) mg/l or mcg/ml mg/l or mcg/ml V:/data/Forms/Mening Page 4 of 6 Jan26/20

F. TREATMENT IN HOSPITAL: F.1. Indicate antibiotics used in diagnosing hospital to treat this individual before culture and sensitivity results were available: a) Penicillin/Ampicillin b) Cefotaxime or Ceftriaxone c) Vancomycin d) Other, specify: /NA F.2. Once culture results and/or susceptibilities were available, what antibiotics were used to treat this individual: a) Penicillin/Ampicillin b) Cefotaxime or Ceftriaxone /NA c) Other, specify: F.3. If meningitis was diagnosed (Sect. C.2. = 3), were IV corticosteroids (eg. dexamethasone) used within the first 24 hours of diagnosis? If not meningitis, skip to section G. If yes: Type: G. LEVEL OF CARE REQUIRED FOR THIS INFECTION: G.1. 1 = admitted to hospital Was individual: 2 = already in hospital for another reason 3 = treated as outpatient G.2. Duration of hospital stay for this illness (combined stays if more that one hospital provided acute care): days G.3. Was individual in any ICU? If yes, i) days combined number of days. ii) assisted ventilation? iii) blood pressure support using pressors? H. OUTCOME: H.1. Enter outcome code: 1. Patient recovering, completing course of antibiotics and will be discharged home OR to other facility primarily to complete course of antibiotic therapy. 2. Patient recovering, completed course of antibiotics but remained in hospital because of other non-meningococcal related illness. 3. Patient recovering, completed course of antibiotics and was transferred to rehabilitation facility or team for management of sequelae. 4. Died of reported infection or sequelae 5. Died of other cause Date of outcome V:/data/Forms/Mening Page 5 of 6 Jan 26/20

K. COMPLICATIONS OR SEQUELAE: K.1. Were there any complications or sequelae of infection? If no or n/a, skip section K. 3 = n/a (in case of death) If Yes, a) Time interval between admission and reporting of sequelae: 1 = <2 months 2 = 2 - <6 months 3 = >6 months b) Type(s) of sequelae? i) Amputation (tissue loss)? If yes, indicate location(s): (write N/A in unused boxes) 1 = head, specify: 2 = upper extremities: 3 = trunk, specify: 4 = lower extremities: 5 = other, specify: ii) Skin scarring? If yes, indicate location(s): (write N/A in unused boxes) 1 = head 2 = neck 3 = upper extremities 4 = trunk 5 = lower extremities 6 = other, specify: iii) Deafness? If yes, severity: left right 1 = mild 2 = moderate 3 = severe 4 = none iv) Renal failure? If yes, dialysis dependent? v) Seizure disorder? vi) Developmental delay or learning impairment? vii) Paralysis? viii) Other, specify: Reviewed by Investigator: yes no Completion date of : Nurse monitor s initials: V:/data/Forms/Mening Page 6 of 6 Jan 26/20